PITTSBURGH, May 6 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release Tablets, 60mg/120mg.

Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended- release Tablets are the generic version of Aventis Pharmaceuticals' Allegra-D^® Extended-release Tablets.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

SOURCE  Mylan Laboratories Inc.
    -0-                             05/06/2004
    /CONTACT:  Media, Heather Bresch, +1-724-514-1800, or Investor, Kris King,
+1-724-514-1800, both of Mylan Laboratories Inc./
    /Web site:  http://www.mylan.com/
    (MYL)

CO:  Mylan Laboratories Inc.; U.S. Food and Drug Administration
ST:  Pennsylvania
IN:  MTC HEA
SU:

WB-JJ 
-- CLTH076 --
8122 05/06/2004 13:28 EDT http://www.prnewswire.com